GlassScriptPhysician profile
Brian R Bea
NPI 1619915808
$2,982.20
in general payments reported to CMS, 2019-2025
25 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $601 · 2023: $595 · 2024: $432 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.23 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $379.16 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $300.69 | 2021-2023 | Spravato |
| Esperion Therapeutics, INC. | $228.96 | 2021-2022 | |
| Lilly USA, LLC | $216.76 | 2022-2025 | Jardiance, Emgality, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $191.09 | 2021-2025 | Eliquis, Camzyos |
| Lundbeck LLC | $155.30 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $146.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $110.88 | 2021-2023 | |
| Glaxosmithkline, LLC. | $90.15 | 2024-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $81.64 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $77.28 | 2021 | |
| Gilead Sciences, INC. | $73.16 | 2021-2024 | |
| Pfizer INC. | $57.17 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.11 | 2023-2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $44.98 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $37.60 | 2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.33 | 2025 | Rexulti |
| Boston Scientific Corporation | $19.49 | 2021 | |
| Hologic Sales and Service, LLC | $18.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.62 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $15.59 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $14.47 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.